Why Life Science Tech Pilots Fail After The Demo — And How To Avoid It
By Lukasz Lazewski, CEO and cofounder, LLInformatics
If you are evaluating clinical or life science technology this year, the demo you are about to see is the least reliable part of the purchase. I say that as someone who builds this software for a living: I can put a working proof of concept in front of a buyer in a matter of hours — and so can most competent teams. That is not a selling point. It is the reason so many life science technology projects quietly fail, and it is the first thing you should account for before you sign anything.
What A Demo Actually Proves
Start with what a demo actually is. A proof of concept exists to answer one question quickly: Is this idea worth pursuing? To get you an answer fast, a team strips away almost everything that makes software hard. They use clean, curated data. They run it in an environment they control. They ignore the dozen systems it will eventually have to talk to. They skip the audit trail, the access controls, the validation evidence, and the failure modes. None of that is cheating. It is the correct way to test an idea. The problem is what you are invited to conclude from it. A demo that works is proof the idea has promise. It is not proof that anyone can ship, run, and defend it in your environment, and the gap between those two things is where budgets go to die.
The Odds You Are Betting Against
That gap is not a rare event you can hope to dodge. The pattern is well documented: MIT's Project NANDA reported in 2025 that 95% of organizations were getting zero return on their generative AI spending, and that only 5% of custom enterprise AI tools reach production. Gartner, in July 2024, predicted that at least 30% of generative AI projects would be abandoned after proof of concept, citing poor data quality, inadequate risk controls, and escalating costs. Digital medicine even has a name for the affliction: "pilotitis," the chronic failure of promising pilots to scale into routine practice. When you sit down in front of a demo, that is the base rate you are betting against. Assume it applies to you until the vendor shows you why it does not.
Make Them Show You The Hard Part
So, make them show you. The useful move is to ask what changes the moment this goes from "it works" to "it works for real patients, real researchers, and real auditors." Your clean demo data set is replaced by fragmented data spread across EHRs, trial systems, and legacy databases, in formats that disagree with one another, so ask how the product behaves on your data, not theirs. A model that was accurate on the bench starts to drift in the field. When researchers externally validated a widely deployed proprietary sepsis model, it caught only about a third of cases at the vendor's recommended alerting threshold, well short of the developer's own reported figures. If a supplier cannot tell you how they will detect and manage that drift after go-live, you have found a risk, not a product.
Where The Demo Goes Silent
The compliance layer is where the demo is most silent, and where you are most exposed. Every record in a regulated system needs an audit trail showing who changed what, when, and why, without ever obscuring the previous value. Signatures have to be attributable and defensible. Under FDA rules, those are not optional, and they are almost never in the version you were shown. The system also has to be validated for its intended use, in your environment, and here is the part buyers miss: that obligation does not transfer with the purchase order. The FDA's final Computer Software Assurance guidance, issued in 2025, allows a lighter, risk-based approach to that work, but it does not remove it, and a vendor cannot simply hand you a validated system and call it done. In Europe, the AI Act now treats much of this software as high risk, with duties around data governance, human oversight, logging, and post-market monitoring that a pilot was never built to carry. The deadlines are moving; the 2026 Digital Omnibus has pushed the high-risk dates out, but the obligations are not going away. Before you buy, make the supplier walk you through how each of these is handled, and treat "we'll deal with that later" as a price you will pay twice.
Buy The Team, Not The Demo
There is one more thing to probe, and it is about the people, not the software. Building a fast proof of concept and operating a compliant product in daily use are close to opposite disciplines. One rewards speed, improvisation, and a willingness to throw work away. The other rewards stability, documentation, and the patience to make something “boring” and reliable. Very few teams hold both at once, and the ones that try often do neither well. So the team that dazzled you in the demo is not automatically the team that will still be standing behind the product in two years. Ask who operates it after launch, whether they have done it before in a regulated setting, and what happens when something breaks at scale. Remember that you are not buying the demo, but the decade that follows it.
Treat The Purchase As A Risk Assessment
None of this requires you to become an engineer. It requires you to treat the purchase as a feasibility and risk assessment. Before you commission a pilot or sign for a platform, decide what the production version has to be true to, and put that in front of the vendor at the start. Know which systems it must integrate with and who owns the data on each side. Establish whether this is the kind of system that has to be formally validated and what evidence a regulator would expect to see. You do not need any of that built into the demo. You need to know it exists, so the demo does not quietly bake in shortcuts that get torn out and rebuilt later, on your budget and your timeline.
A working demo tells you an idea is worth pursuing, and that is genuinely valuable. In a startup, we would call it verifying product-market fit. But proving the idea is the easy part; building around it and scaling it is where the real work starts. The demo tells you almost nothing about whether the thing can be shipped, integrated, validated, and defended in front of a regulator, and in life sciences, that second question is the only one that ends up mattering. The buyers who come out ahead ask it first, while the demo is still a sketch, not after they have already promised their own board a product.
About The Author:
Lukasz Lazewski is a software engineer and entrepreneur with nearly two decades of experience advising technology companies across Europe and the United States. He began his career as a software engineer at AOL and Advertising.com before moving into CTO and senior leadership roles at companies including Viewlabs, AUPEO! (acquired by Panasonic), and Zenloop. In 2012, he co-founded LLInformatics, a software consultancy of 130+ senior specialists, where he now serves as CEO, helping enterprises modernize legacy systems and deliver compliance-ready software on time and on budget.